User Guide
Why can I only view 3 results?
You can also view all results when you are connected from the network of member institutions only. For non-member institutions, we are opening a 1-month free trial version if institution officials apply.
So many results that aren't mine?
References in many bibliographies are sometimes referred to as "Surname, I", so the citations of academics whose Surname and initials are the same may occasionally interfere. This problem is often the case with citation indexes all over the world.
How can I see only citations to my article?
After searching the name of your article, you can see the references to the article you selected as soon as you click on the details section.
 Views 17
 Downloands 1
Investigation of Molecular Changes in RAS/RAF/MEK/MAPK Pathway in Serous Adenocarcinomas and Serous Borderline Tumors of Ovary
2020
Journal:  
Ankara Üniversitesi Tıp Fakültesi Mecmuası
Author:  
Abstract:

Objectives: To investigate MAP Kinase (p38), c-Fos, c-Jun and c-Myc; in RAS/RAF/MEK/MAPK pathway by immunohistochemically in high grade serous adenocarcinomas, serous borderline tumors and benign lesions of the ovary. Materials and Methods: Twelve serous borderline tumors, 41 high-grade serous carcinomas and 19 cases of serous papillary cystadenofibromas, serous cystadenomas; p38, c-Myc, c-Jun and c-Fos immunohistochemical staining were performed. Results: In borderline and benign lesions, diffuse and severe staining was observed in all cases with c-Fos, whereas focal and mild staining was observed in only 16 of the serous adenocarcinomas (p<0.05). While nuclear staining was not observed in any of the serous adenocarcinomas with c-Myc, mild and focal staining was detected in four of the borderline tumors and 16 of the benign tumors. There was a statistically significant difference in nuclear staining between the three groups (p<0.05). Nuclear staining was detected in four borderline tumors, in seven serous adenocarcinomas and in eight cases in the benign tumor group with c-Jun. These stainings were not statistically significant. Moderate staining was observed in 18 of benign tumors and in all borderline tumors and mild staining in eight of serous adenocarcinomas. A statistically significant difference was found between benign and serous borderline tumors and serous adenocarcinomas (p<0.05); there was no difference between benign tumors and borderline tumors. Conclusion: In borderline serous tumors; the nuclear expression of p38, c-Myc and c-Fos is statistically different from serous adenocarcinomas that proves the activation of the RAS/RAF/MEK/MAPK pathway in borderline tumors. In practical life, although it may seem usable in the cases that these tumors cannot be separated from serous adenocarcinoma; that we could not include in this study; the staining pattern in low-grade serous adenocarcinomas is unknown. Therefore, it should be investigated in large case series whether low grade serous adenocarcinomas and borderline tumors show similar expression patterns.

Keywords:

Investigation of Molecular Changes in RAS/RAF/MEK/MAPK Pathway in Serous Adenocarcinomas and Serous Borderline Tumors of Ovary
2020
Author:  
Abstract:

Objectives: To investigate MAP Kinase (p38), c-Fos, c-Jun and c-Myc; in RAS/RAF/MEK/MAPK pathway by immunohistochemically in high grade serous adenocarcinomas, serous borderline tumors and benign lesions of the ovarian. Materials and Methods: Twelve serous borderline tumors, 41 high-grade serous carcinomas and 19 cases of serous papillary cystadenofibromas, serous cystadenomas; p38, c-Myc, c-Jun and c-Fos immunohistochemical staining were performed. Results: In borderline and benign lesions, diffuse and level staining was observed in all cases with c-Fos, whereas focal and mild staining was observed in only 16 of the serous adenocarcinomas (p<0.05). While nuclear staining was not observed in any of the serous adenocarcinomas with c-Myc, mild and focal staining was detected in four of the borderline tumors and 16 of the benign tumors. There was a statistically significant difference in nuclear staining between the three groups (p<0.05). Nuclear staining was detected in four borderline tumors, in seven serous adenocarcinomas and in eight cases in the benign tumor group with c-Jun. These stainings were not statistically significant. Moderate staining was observed in 18 of benign tumors and in all borderline tumors and mild staining in eight of serous adenocarcinomas. A statistically significant difference was found between benign and serous borderline tumors and serous adenocarcinomas (p<0. There was no difference between benign tumors and borderline tumors. Conclusion: In borderline serous tumors; the nuclear expression of p38, c-Myc and c-Fos is statistically different from serous adenocarcinomas that proves the activation of the RAS/RAF/MEK/MAPK pathway in borderline tumors. In practical life, although it may seem usable in the cases that these tumors cannot be separated from serous adenocarcinoma; that we could not include in this study; the staining pattern in low-grade serous adenocarcinomas is unknown. Therefore, it should be investigated in large case series whether low-grade serous adenocarcinomas and borderline tumors show similar expression patterns.

Keywords:

Citation Owners
Information: There is no ciation to this publication.
Similar Articles












Ankara Üniversitesi Tıp Fakültesi Mecmuası

Field :   Sağlık Bilimleri

Journal Type :   Ulusal

Metrics
Article : 1.037
Cite : 25.046
2023 Impact : 0.191
Ankara Üniversitesi Tıp Fakültesi Mecmuası